Home » Healthcare » Pharmaceuticals » Acute Myeloid Leukemia (AML) Therapeutics Market

Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs Type (Top 3 Countries, Chemotherapy Drugs, Pipeline Drugs) – Growth, Future Prospects And Competitive Analysis, 2017 – 2025

Published: | Report ID: 1267 | Report Format : PDF

Market Insights

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer characterized by the abnormal production of myeloid blasts in the bone marrow and peripheral blood. The rising incidence of AML, a higher number of unmet needs, the expected launch of ideal molecules, and technological advances are prime factors driving the growth of the AML therapeutics market globally.

The report titled “Acute Myeloid Leukemia (AML) Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall AML therapeutics market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug type (chemotherapy drugs and pipeline drugs) and different geographical regions.

Geographically, the global AML therapeutics market is studied for the following regional markets:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • rest of Latin America

Middle East and Africa

  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global AML therapeutics market. Pipeline analysis and global epidemiology data have been included in the report. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global AML therapeutics market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global AML therapeutics market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global AML therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on the drug type, the global acute myeloid leukemia (AML) therapeutics market is segmented as follows:

Chemotherapy Drugs

  • Cytarabine
  • Anthracyclines
  • Daunorubicin
  • Idarubicin
  • Mitoxantrone
  • Etoposide
  • Other

Pipeline Drugs

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that is characterized by an overproduction of immature myeloblasts or leukemic blasts. The AML therapeutics market is expected to show significant market growth during the forecast period, primarily due to the growing prevalence of leukemia and the presence of ideal pipeline molecules.

Treatment of AML is typically divided into two phases: induction therapy and post-remission therapy. It is studied that, in the base year 2016, cytarabine was a major revenue-generating segment due to its effectiveness, and hence it is a primary component of chemotherapeutic regimens. It is estimated that newly approved drugs such as gemtuzumab ozogamicin, Vyxeos, and midostaurin will show significant market growth during the forecast period. It is believed that the presence of strong pipeline molecules such as Bosutinib, Vosaroxin, Omacetaxine mepesuccinate, Venetoclax, and Quizartinib would assist the AML therapeutics market growth during the forecast period of 2017–2025.

For the purpose of this study, the global acute myeloid leukemia (AML) therapeutics market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Acute myeloid leukemia (AML) is a type of blood cancer characterized by the expansion of myeloid blasts in the bone marrow and peripheral blood. According to Globocan, theworldwide prevalence of AML is approximately 1.5% and 1.4% for males and females, respectively. It is observed that currently, North America is dominating the AML therapeutics market due to its developed healthcare infrastructure, advanced technologies, the higher number of targeted populations, surge in funding by government agencies, and regulatory approval of newer molecules.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Furthermore, an increase in the incidence of AML and the upcoming regulatory approval of newer molecules would boost the AML therapeutics market during the forecast period. The American Cancer Society recorded approximately 21,380 new cases and 10,590 deaths from AML in the United States in 2017. It is estimated that Asia Pacific will show significant AML therapeutics market growth during the forecast period due to developing healthcare infrastructure, an increasing incidence of AML, and rising treatment awareness.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Snapshot
2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
2.3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share, by Geography, 2016 (Value %)

Chapter 3 Acute Myeloid Leukemia (AML) Therapeutics Market Analysis
3.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Acute Myeloid Leukemia (AML) Therapeutics
3.4 Global Epidemiology of Acute Myeloid Leukemia (AML)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Acute Myeloid Leukemia (AML) Therapeutics Market

Chapter 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
4.1 Overview
4.2 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
4.3 Top 3 Countries
4.4 Chemotherapy Drugs
4.4.1 Cytarabine
4.4.2 Anthracyclines
4.4.3 Etoposide
4.4.4 Other
4.5 Pipeline Drugs

Chapter 5 Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.2.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.3.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.5.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
6.3 Boehringer Ingelheim GmbH
6.4 Bristol Myers Squibb
6.5 Celegene Corporation
6.6 Cephalon Inc.
6.7 Eisai Co. Ltd.
6.8 Eli Lilly and Company
6.9 Genzyme Corporation (A subsidiary of Sanofi S.A.)
6.10 Jazz Pharmaceuticals, Inc.
6.11 Novartis AG
6.12 Pfizer Inc.

List of Figures

FIG. 1 Acute Myeloid Leukemia (AML) Therapeutics Market: Research Methodology
FIG. 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2016 (US$ Mn)
FIG. 3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2016
FIG. 6 Global Chemotherapy Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Acute Myeloid Leukemia (AML) Cytarabine Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Acute Myeloid Leukemia (AML) Anthracyclines Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Acute Myeloid Leukemia (AML) Etoposide Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Other Drugs in Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Pipeline Drugs in Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Acute Myeloid Leukemia (AML) Therapeutics Market
TABLE 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 3 Top 3 Countries in Global Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 6 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 8 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 12 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 Abbott Laboratories: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Celegene Corporation: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Cephalon Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Genzyme Corporation (A subsidiary of Sanofi S.A.): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Jazz Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Acute Myeloid Leukemia Therapeutics Market?

The market for Acute Myeloid Leukemia Therapeutics Market is expected to reach USD$ 1,025.9 Mn in 2025.

What is the Acute Myeloid Leukemia Therapeutics Market CAGR?

The Acute Myeloid Leukemia Therapeutics Market is expected to see significant CAGR growth over the coming years, at 10.9%.

What is the Forecast period considered for Acute Myeloid Leukemia Therapeutics Market?

The report is forecasted from 2017 -2025.

What is the base year considered for Acute Myeloid Leukemia Therapeutics Market?

The base year of this report is 2016.

Who are the major players in this market?

bbott Laboratories,Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical),Boehringer Ingelheim GmbH,Bristol Myers Squibb,Celegene Corporation. are some of the major players in the global market.

Prostate Cancer Market

Published:
Report ID: 36273

Antineoplastic Agents Market

Published:
Report ID: 36065

US Retail Pharmacy Market

Published:
Report ID: 32801

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN